Solmaz AghaAmiri

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (39)

• Figure S1 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704097
  +Save
• Data from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.c.7700661
  +Save
• Table S2 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704055
  +Save
• Table S1 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704058
  +Save
• Figure S9 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704064
  +Save
• Figure S8 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704070
  +Save
• Figure S7 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704073
  +Save
• Figure S6 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704076
  +Save
• Figure S5 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704079
  +Save
• Figure S4 from Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
  2026 DOI: 10.1158/0008-5472.32704085
  +Save